In this study, we aimed to explore the multifactor Cox regression model and its influencing factors for parotid cancer using the publicly available data and research resources from the Surveillance, Epidemiology, and End Results (SEER) database established by the American Cancer Research Center. We conducted a retrospective analysis and observed statistical data from 1653 cases of parotid cancer patients. We utilized a multifactor Cox regression model to screen for risk factors, evaluated the model using the C-index, assessed the accuracy of the 3-year and 5-year survival models through ROC curve analysis, and predicted the 3-year and 5-year survival probabilities using calibration plots. The results were presented using column line graphs.  The multifactor Cox regression model analyzed age, gender, race, T stage, and N stage as risk factors for parotid cancer. The data revealed that the older the age, the higher the likelihood of developing parotid cancer, with a significantly higher proportion observed in White males compared to Black and Asian individuals. ROC analysis yielded an AUC of 0.84 for 3-year survival and 0.842 for 5-year survival. Parotid cancer, regardless of its benign or malignant nature, does not exhibit significant age restrictions, but it is commonly found in middle-aged and elderly populations. Clinical recommendations include regular monitoring of symptoms in parotid cancer patients, assessing T, N, M staging, and patient prognosis, with surgery being the optimal treatment modality for parotid cancer.

Lixin Wang, Binying Huang. Multifactor Cox Regression Model Analysis of Parotid Cancer Based on the SEER. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 6: 53-59. https://doi.org/10.25236/IJFM.2024.060608.

[1] Du Zhonghong. (2011). Clinical Treatment Analysis of 127 Cases of Parotid Gland Tumors. Journal of Oral Medicine Research, 27(5), 417-418.

[2] Huang Aiyu, Zhang Mengyin, & Xue Ming. (1991). Comprehensive Treatment of Advanced Parotid Cancer (with an Analysis of 41 Cases). Shanghai Medicine, 14(10), 575-579.

[3] Ye J, Li J. [Applied anatomic and biomechanical study on reconstruction of posterolateral complex of knee] [J]. Chinese journal of reparative and reconstructive surgery, 2010, 24(10):1199-1203. DOI:http://dx.doi.org/.

[4] Katz, A. D. (1975). Unusual lesions of the parotid gland. Journal of Surgical Oncology, 7(3), 219-235.

[5] Chang, J., Hong, H., Ban, M., Shin, Y., Kim, W., Koh, Y., & Choi, E. (2015). Prognostic Factors and Treatment Outcomes of Parotid Gland Cancer. Otolaryngology-Head and Neck Surgery, 153(6), 981-989. 

[6] Shang Biao, Wei Qichun, Wang Kejing, Guo Liang, & Ge Minghua. (2008). Clinical Analysis of 135 Cases of Parotid Cancer. Zhejiang Medicine, 30(10), 1110-1111.

[7] Fan Dexin. (2004). Clinical Analysis of 168 Cases of Parotid Gland Tumors. Journal of Oral and Maxillofacial Surgery, 14(4), 354-356.

[8] Guo Liang, Wang Kejing, Liu Aihua, & Shang Jinbiao. (1999). Treatment Evaluation of 244 Cases of Parotid Cancer. Otolaryngology: Head and Neck Surgery, 6(3), 150-153.

[9] Ferreira, P. C., Amarante, J. M., Rodrigues, J. M., Pinho, C. J., Cardoso, M. A., & Reis, J. C. (2005). Parotid Surgery: Review of 107 Tumors. Int Surg, 200590, 160-166.

[10] Fan Fengyun, Wei Wensheng, Guo Yan, Shi Mei, & Xu Demen. (2004). Evaluation of Postoperative Radiotherapy for Parotid Cancer. Journal of Practical Oral Medicine, 20(6), 678-680.

[11] Choi, S. Y., Lee, E., Kim, E., Chung, M. K., Son, Y. I., Baek, C. H., & Jeong, H. S. (2021). Clinical outcomes of bulky parotid gland cancers: need for self-examination and screening program for early diagnosis of parotid tumors. BMC cancer, 21, 1-9.

[12] Liu, Z., Wang, Q., & Zhao, Y. (2019). Expression and Clinical Significance of P16, Ki-67, and CyclinD1 in Oral Tissues of Oral Cancer Patients. Modern Medicine, 47, 1-4.

[13] Schlichting, P., Christensen, E., Andersen, P. K., Fauerholdt, L., Juhl, E., Poulsen, H., ... & Copenhagen Study Group for Liver Diseases. (1983). Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology, 3(6), 889-895.

[14] Longato, E., Vettoretti, M., & Di Camillo, B. (2020). A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models. Journal of biomedical informatics, 108, 103496. 

[15] Hartman, N., Kim, S., He, K., & Kalbfleisch, J. D. (2023). Pitfalls of the concordance index for survival outcomes. Statistics in Medicine, 42(13), 2179-2190.

[16] Hoo, Z. H., Candlish, J., & Teare, D. (2017). What is an ROC curve? Emergency Medicine Journal, 34(6), 357-359.

[17] Metz, C. E. (1978, October). Basic principles of ROC analysis. In Seminars in nuclear medicine (Vol. 8, No. 4, pp. 283-298). WB Saunders.

[18] Narkhede, S. (2018). Understanding auc-roc curve. Towards data science, 26(1), 220-227.

[19] Marzban, C. (2004). The ROC curve and the area under it as performance measures. Weather and Forecasting, 19(6), 1106-1114.

[20] Zhang, Z., & Kattan, M. W. (2017). Drawing Nomograms with R: applications to categorical outcome and survival data. Annals of translational medicine, 5(10).